PMID

Data

Article Title

Organization

GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved

Genentech

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.

Pharmaron-Beijing

Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists ors1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.

Universit£

Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.

Institut F£R Pharmazeutische Und Medizinische Chemie Der Westf£Lischen Wilhelms-Universit£T M£Nster

Some non-conventional biomolecular targets for diamidines. A short survey.

Xavier University of Louisiana

Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.

University of Strasburg

5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.

Novartis Pharma

2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.

Astrazeneca Pharmaceuticals

Assessment of structurally diverse philanthotoxin analogues for inhibitory activity on ionotropic glutamate receptor subtypes: discovery of nanomolar, nonselective, and use-dependent antagonists.

University of Copenhagen

Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.

Friedrich-Schiller-Universitat Jena

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

Merck Research Laboratories

Orally efficacious NR2B-selective NMDA receptor antagonists.

Merck Research Laboratories

Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.

Parke-Davis Pharmaceutical Research